TheraJect, Inc. is a preclinical stage biopharmaceutical
company committed to the drug delivery including vaccines
via a novel, needle-free transdermal technology.

TheraJect is focused on enhancing the efficacy of existing
vaccines, enabling new vaccines and expanding the global
vaccine market.
The TheraJect patch consists of an array of dissolvable
microneedles that create superficial pathways through the
skin's dead barrier layer, allowing transport of
macromolecules into the viable epidermis.

The array is held in place by a traditional adhesive patch.
The microneedles dissolve within minutes in the interstitial
fluid, delivering the drug or vaccine.

The microneedle components are selected from a broad
range of dissolving materials, all of which are either GRAS
or have been used in injectibles.

The drug or vaccine to be delivered is mixed with the
microneedle materials to form a hydrogel, poured into a
mould, dried and then cut and assembled with an adhesive
patch. This extremely simple, “fill and finish” like process is
eminently scalable.